Trial Profile
A Randomized, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Sintilimab (IBI308) in Combination With Gemcitabine and Platinum-Based Chemotherapy vs. Placebo in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Treatment for Patients With Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer (NSCLC) (ORIENT-12
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-12
- Sponsors Innovent Biologics
- 27 Feb 2023 Status changed from active, no longer recruiting to completed.
- 22 Sep 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 18 May 2022 Results assessing patient-reported outcomes ,presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.